Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review

NEXT STORY
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan
PREV STORY
PD Theranostics, Inc. Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time

Milestone for antibody targeting TIM-3 triggers $5 million payment to Five PrimeBMS extends research ...

author_avatar
NASDAQ Market News

VALNEVA Evaluating Development of Zika Vaccine as Virus Spreads Through the Americas

LYON, France, Feb. 2, 2016 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva" or "the Company"), ...

author_avatar
NASDAQ Market News

Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference

author_avatar
NASDAQ Market News